During discussions, it was noted that the pharmaceutical industry tends to work with a similar pool of sites with a proven track record. With an ongoing lack of patient representation, particularly from the Black community, the industry must be more deliberate with their site-selection process to enhance trial diversity:
Pharma companies need to make sure they update their feasibility questionnaires so that sites can be proud of the fact that they have a diverse community culture to bring these types of patients into the studies.
Dr. Fabian Sandoval, Physician Focus Group Participant
Physicians also provided feedback that the pharmaceutical industry has historically been perceived as reluctant to ask questions outright about diversity in patient populations or staff for fear of causing offense. Without resolution, this could limit progress toward proactively inclusive practices that improve representation within clinical research.